EPOSERIN Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eposerin

pfizer italia s.r.l. - ceftizoxima - ceftizoxima

CEFODIE Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

cefodie

mediolanum farmaceutici s.p.a. - cefonicid - cefonicid

MONOBIOS Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

monobios

laboratorio farmaceutico c.t. s.r.l. - cefonicid - cefonicid

MARBOCYL BOLUS Italia - italiano - Ministero della Salute

marbocyl bolus

vetoquinol s.a. - marbofloxacina - marbofloxacina - 50 milligrammo (i), marbofloxacina - 50 mg - marbofloxacin

Arikayce liposomal Unione Europea - italiano - EMA (European Medicines Agency)

arikayce liposomal

insmed netherlands b.v. - amikacin sulfate - infezioni del tratto respiratorio - antibatterici per uso sistemico, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

MEFOXIN Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mefoxin

i.b.n. savio s.r.l - cefoxitina - cefoxitina

TAXIME Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

taxime

pharmatex italia s.r.l. - cefotaxima - cefotaxima

Ertapenem SUN Unione Europea - italiano - EMA (European Medicines Agency)

ertapenem sun

sun pharmaceutical industries (europe) b.v. - ertapenem sodico - infezioni batteriche - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 e 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..